Windtree Therapeutics Inc is a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases. The company develops product candidates targeting cardiovascular and oncology indications, including istaroxime for acute heart failure and cardiogenic shock, rostafuroxin for genetically associated hypertension, and aPKCi inhibitor for topical and oral oncology applications. Windtree Therapeutics Inc also pursues…
Windtree Therapeutics Inc is a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases. The company develops product candidates targeting cardiovascular and oncology indications, including istaroxime for acute heart failure and cardiogenic shock, rostafuroxin for genetically associated hypertension, and aPKCi inhibitor for topical and oral oncology applications. Windtree Therapeutics Inc also pursues preclinical SERCA2a activator compounds for heart failure treatment and engages in licensing activities to monetize its intellectual property and development programs.
Windtree Therapeutics Inc generates revenue primarily through licensing agreements, partnership arrangements, and potential acquisition strategies. The company has entered into licensing deals with entities such as Lee’s Pharmaceutical (HK) Ltd. for the development and commercialization of istaroxime and related cardiovascular candidates in Greater China. Additionally, Windtree Therapeutics Inc acquired assets from Varian Biopharmaceuticals, Inc., including aPKCi inhibitor platforms, to expand its oncology pipeline. The company announced a new corporate strategy in January 2025 to become a revenue-generating biotech firm through acquisitions of small companies with FDA-approved products while continuing to advance its internal development programs.
The company operates through the following segments: cardiovascular programs and oncology programs.
- Cardiovascular programs: This segment includes the development of istaroxime for acute heart failure and cardiogenic shock, rostafuroxin for hypertension in patients with a specific genetic profile, and preclinical SERCA2a activator compounds for heart failure treatment. Istaroxime has received Fast Track designation from the U. S. Food and Drug Administration for acute heart failure and has been evaluated in multiple Phase 2 clinical trials showing improvements in systolic blood pressure and cardiac function. Rostafuroxin has demonstrated efficacy in Caucasian patients in treatment-naïve hypertension during Phase 2b clinical trials. The segment also encompasses oral and intravenous SERCA2a activator product candidates currently in preclinical development for both acute decompensated and chronic outpatient heart failure.
- Oncology programs: This segment centers on the development of aPKCi inhibitor in topical and oral formulations for potential application in rare and broad oncology indications. The aPKCi inhibitor platform was acquired through an Asset Purchase Agreement with Varian Biopharmaceuticals, Inc., which included worldwide exclusive rights to a class of PKC inhibitors shown to play a key role in cancer development signaling pathways. Preclinical data indicate dose-dependent anti-tumor activity in murine and human basal cell carcinoma cell lines and xenograft models of non-small cell lung cancer and pancreatic ductal carcinoma. The topical formulation is being prioritized for cutaneous malignancies such as basal cell carcinoma due to potential for limited systemic side effects, while the oral formulation targets solid tumors including non-small cell lung, pancreatic, and ovarian cancers.
Windtree Therapeutics Inc operates in a highly competitive biotechnology industry where it faces competition from both large pharmaceutical companies and other biotechnology firms developing therapies for respiratory and cardiovascular indications. The company’s competitive advantages include its first-in-class dual-mechanism istaroxime, proprietary SERCA2a activator compounds, and exclusive licensing rights to innovative oncology platforms derived from the Varian asset acquisition. Windtree Therapeutics Inc also benefits from orphan drug and Fast Track designations granted by regulatory agencies, which may provide developmental and commercial incentives for its product candidates.
Windtree Therapeutics Inc serves patients, healthcare providers, and medical institutions involved in the treatment of acute heart failure, cardiogenic shock, hypertension, basal cell carcinoma, and various solid tumors. The company’s product candidates are intended for use in hospital settings for acute indications such as cardiogenic shock and acute decompensated heart failure, as well as outpatient settings for chronic conditions like hypertension and heart failure. Windtree Therapeutics Inc collaborates with partners such as Lee’s Pharmaceutical (HK) Ltd. and Zhaoke Pharmaceutical (Hefei) Co. Ltd. for regional development and commercialization efforts, particularly in the Greater China region.